Senores Pharma boosts heart health portfolio with acquisition of USFDA approved Enalapril Tablets ANDA from Wockhardt

Ahmedabad: Senores Pharmaceuticals Limited (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreement to acquire the USFDA-approved Abbreviated New Drug Application (“ANDA”) for Enalapril Maleate Tablets 2.5mg, 5mg, 10mg and 20mg from Wockhardt Limited.

Enalapril is indicated as a treatment of hypertension, heart failure, and asymptomatic left ventricular dysfunction.

The market size of Enalapril Tablet in the USA was ~USD 28.60 Mn (MAT December 2024) as per IQVIA and ~USD 109.24 Mn (MAT March 2025) as per the specialty data aggregator Symphony.

The acquisition will be funded through the Initial Public Offer (“IPO”) proceeds raised by SPL. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.

Senores Pharmaceuticals Limited is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms. The companies’ current portfolio includes 61 ANDA and 22 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets, catering to more than 40 countries. The company currently has approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 280 product registrations and 630 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (“API”). Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA, TAA & BAA compliant for controlled substances and government supplies & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda.